Mind Medicine (MindMed) Inc. (MNMD): Price and Financial Metrics


Mind Medicine (MindMed) Inc. (MNMD): $5.75

0.01 (+0.17%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add MNMD to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

MNMD Stock Price Chart Interactive Chart >

Price chart for MNMD

MNMD Price/Volume Stats

Current price $5.75 52-week high $44.10
Prev. close $5.74 52-week low $5.52
Day low $5.52 Volume 1,281,900
Day high $6.32 Avg. volume 454,204
50-day MA $9.97 Dividend yield N/A
200-day MA $14.26 Market Cap 163.80M

Mind Medicine (MindMed) Inc. (MNMD) Company Bio


Mind Medicine (MindMed) Inc., a psychedelic medicine biotech company, discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances, including Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative, 18-MC. The company is headquartered in New York, New York.


MNMD Latest News Stream


Event/Time News Detail
Loading, please wait...

MNMD Latest Social Stream


Loading social stream, please wait...

View Full MNMD Social Stream

Latest MNMD News From Around the Web

Below are the latest news stories about MIND MEDICINE (MINDMED) INC that investors may wish to consider to help them evaluate MNMD as an investment opportunity.

MindMed Collaborators Dose First Patient in Phase 1 Investigator-Initiated Trial of MDMA-Like Substances

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced the first patient has been dosed in a Phase 1 investigator-initiated study led by MindMed collaborator Prof. Dr. Matthias Liechti at University Hospital Basel (UHB). The study aims to evaluate the effects of MDMA-like substances, including MDA, Lys-MDMA, Lys-MDA, versus a placebo in healthy vo

Yahoo | September 20, 2022

CFVI Stock Heats Up Ahead of Rumble SPAC Merger Vote

CF Acquisition (CFVI) stock is getting a boost on Wednesday as investors prepare to vote on a SPAC merger with Rumble tomorrow.

William White on InvestorPlace | September 14, 2022

MindMed (MNMD) Stock Regains Nasdaq Compliance

MindMed (MNMD) stock is in the news Wednesday after the psychedelic medicine company regained Nasdaq minimum price compliance.

William White on InvestorPlace | September 14, 2022

What Is Going on With BioAffinity (BIAF) Stock Today?

BioAffinity (BIAF) stock is rising higher on Wednesday after the company announced the publication of its research in PLOS ONE.

William White on InvestorPlace | September 14, 2022

MindMed Announces Compliance with Nasdaq Listing Requirements

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that it has received a letter from The Nasdaq Stock Market LLC advising the Company that it has regained compliance with Nasdaq's minimum bid price listing requirement. The Company has satisfied the terms for continued listing on the Nasdaq Capital Market by complying with the minimum bid pric

Yahoo | September 14, 2022

Read More 'MNMD' Stories Here

MNMD Price Returns

1-mo -51.54%
3-mo -42.53%
6-mo -65.47%
1-year -84.16%
3-year N/A
5-year N/A
YTD -72.22%
2021 -54.75%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5353 seconds.